EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Clinical experiences in oral antidiabetic therapy with sulphonylureas and biguanides






Australian and New Zealand Journal of Medicine 1: Suppl 2:47-56

Clinical experiences in oral antidiabetic therapy with sulphonylureas and biguanides



Accession: 042565124

PMID: 5005131



Related references

Haupt, E.; Knick, B.; Koschinsky, T.; Liebermeister, H.; Schneider, J.; Hirche, H., 1991: Oral antidiabetic combination therapy with sulphonylureas and metformin. In a multicentre trial in general practice, a total of 1823 type 2 diabetics, not adequately controlled by diet and maximal sulphonylurea therapy, were treated with additional metformin 850--2 550 mg/d for 12 weeks. The average postprandial blood...

Schoeffling K., 1971: Clinical experiences in oral anti diabetic therapy with sulfonyl ureas and biguanides. Australian & New Zealand Journal of Medicine 1(SUPPL 2): 47-56

Gregorio, F.; Filipponi, P., 1988: Biguanides in oral antidiabetic therapy: indications and limitations. Medicina 8(3): 262-268

Augusti, K.T.; Kurup, P.A., 1969: Mode of action of oral hypoglycaemic agents. II. Sulphonylureas & biguanides in rats. Indian Journal of Biochemistry 6(1): 36-39

Patel, J.C.; Dhirawani, M.K.; Doshi, J.C., 1970: Long term observations with oral hypoglycemic drugs: sulphonylureas, biguanides and their combination. Indian Journal of Medical Sciences 24(7): 393-403

Derosa, G.; Salvadeo, S.A.T.; D'Angelo, A.; Ferrari, I.; Mereu, R.; Palumbo, I.; Maffioli, P.; Randazzo, S.; Cicero, A.F.G., 2010: Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. To compare the metabolic effects of acarbose and repaglinide in type 2 diabetic patients who are being treated with a sulphonylurea-metformin combination therapy. The primary endpoint of the study was to evaluate which add-on treatment between aca...

Achelis, J.D.; Maiwald, K.H., 1962: The oral antidiabetic agents. The mode of action of sulphonylureas. Anglo-German Medical Review. Deutsch-Englische Medizinische Rundschau 1: 310-333

Schöffling, K.; Petzoldt, R.; Althoff-Zucker, C.; Beyer, J.; Retiene, K.; Böhle, E.; Kunkel, W., 1969: Clinical experiences with oral antidiabetic HB 419 (glibenclamide). Arzneimittel-Forschung 19(8): Suppl:1439-45

Sieberová, R., 1971: Clinical experiences with administration of oral antidiabetic agent Buformin. Casopis Lekaru Ceskych 110(18): 420-421

Gamble, J.; Simpson, S.H.; Brown, L.C.; Johnson, J.A., 2008: Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis. Although evidence-based guidelines for the treatment of type 2 diabetes mellitus provide clear recommendations for initial therapy, evidence on an optimal treatment strategy after secondary failure is unclear. To compare the efficacy of add-on the...